Pricing Log in Create free account
Friday 6 November 2026 Export ZYME’s income statement to Excel — free account

Zymeworks Inc.

ZYME Healthcare Biotechnology

Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.

Revenue
−90.6%
EPS
−2,166.7%
Free cash flow
−385.5%

Quarter to June 2026, against a year earlier

29.52 0.78 +2.71%
Market cap
$2.0B
P/E
0.0×
Fwd P/E
26.0×
Dividend yield
—
F-score
7/9
Altman Z
11.56
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Zymeworks Inc. (ZYME) P/E ratio

Alert me on P/E ratio

Zymeworks Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 5.6× (January 2023) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 4.2× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
38 more quarters

Against its own ten years

Low 0.0× High 5.6×
Ten-year median 0.0×
Current reading's percentile 90

P/E ratio against peers

Company P/E ratio
COAG Hemab Therapeutics Holdings, Inc. compare n/m
BHVN Biohaven Ltd. compare n/m
LKFT Lakefront Biotherapeutics - Sponsored ADR compare n/m
ZYME Zymeworks Inc. n/m
SEPN Septerna, Inc. compare n/m
VERA Vera Therapeutics, Inc. compare n/m
IMNM Immunome, Inc. compare n/m
AUPH Aurinia Pharmaceuticals Inc compare 6.8×
VCEL Vericel Corporation compare 77.8×
Biotechnology industry median 10.3×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on ZYME